50 related articles for article (PubMed ID: 7474663)
1. Plasma Proteins Modified by Advanced Glycation End Products (AGEs) Reveal Site-specific Susceptibilities to Glycemic Control in Patients with Type 2 Diabetes.
Greifenhagen U; Frolov A; Blüher M; Hoffmann R
J Biol Chem; 2016 Apr; 291(18):9610-6. PubMed ID: 26933035
[TBL] [Abstract][Full Text] [Related]
2. Abeta-2M-amyloidosis and related bone diseases.
Kazama JJ; Yamamoto S; Takahashi N; Ito Y; Maruyama H; Narita I; Gejyo F
J Bone Miner Metab; 2006; 24(2):182-4. PubMed ID: 16502130
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients.
Niwa T; Katsuzaki T; Miyazaki S; Miyazaki T; Ishizaki Y; Hayase F; Tatemichi N; Takei Y
J Clin Invest; 1997 Mar; 99(6):1272-80. PubMed ID: 9077536
[TBL] [Abstract][Full Text] [Related]
4. Amyloid beta 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis.
Niwa T; Katsuzaki T; Miyazaki S; Momoi T; Akiba T; Miyazaki T; Nokura K; Hayase F; Tatemichi N; Takei Y
Kidney Int; 1997 Jan; 51(1):187-94. PubMed ID: 8995733
[TBL] [Abstract][Full Text] [Related]
5. Modification of beta 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum.
Niwa T; Katsuzaki T; Momoi T; Miyazaki T; Ogawa H; Saito A; Miyazaki S; Maeda K; Tatemichi N; Takei Y
Kidney Int; 1996 Mar; 49(3):861-7. PubMed ID: 8648931
[TBL] [Abstract][Full Text] [Related]
6. Ultrastructural localization of advanced glycation end products and beta2-microglobulin in dialysis amyloidosis.
Brancaccio D; Gallieni M; Niwa T; Braidotti P; Coggi G
J Nephrol; 2000; 13(2):129-36. PubMed ID: 10858976
[TBL] [Abstract][Full Text] [Related]
7. Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis.
Miyata T; Taneda S; Kawai R; Ueda Y; Horiuchi S; Hara M; Maeda K; Monnier VM
Proc Natl Acad Sci U S A; 1996 Mar; 93(6):2353-8. PubMed ID: 8637877
[TBL] [Abstract][Full Text] [Related]
8. Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis.
Hou FF; Chertow GM; Kay J; Boyce J; Lazarus JM; Braatz JA; Owen WF
Kidney Int; 1997 May; 51(5):1514-9. PubMed ID: 9150467
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis.
Niwa T; Miyazaki S; Katsuzaki T; Tatemichi N; Takei Y; Miyazaki T; Morita T; Hirasawa Y
Kidney Int; 1995 Sep; 48(3):771-8. PubMed ID: 7474663
[TBL] [Abstract][Full Text] [Related]
10. Beta2-microglobulin and renal bone disease.
Wada T; Miyata T; Sakai H; Kurokawa K
Perit Dial Int; 1999; 19 Suppl 2():S413-6. PubMed ID: 10406556
[TBL] [Abstract][Full Text] [Related]
11. Dialysis-related amyloidosis: pathogenesis focusing on AGE modification.
Niwa T
Semin Dial; 2001; 14(2):123-6. PubMed ID: 11264780
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis, pathogenesis, and treatment of dialysis-related amyloidosis.
Miyata T; Inagi R; Kurokawa K
Miner Electrolyte Metab; 1999; 25(1-2):114-7. PubMed ID: 10207272
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
